Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated by Analysts at Roth Mkm

Roth Mkm started coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a note issued to investors on Friday,Benzinga reports. The firm set a “buy” rating and a $7.00 price target on the stock. Roth Mkm’s price target indicates a potential upside of 274.33% from the company’s current price.

Separately, EF Hutton Acquisition Co. I raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.67.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $1.87 on Friday. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $5.14. The stock has a market cap of $62.53 million, a price-to-earnings ratio of -1.68 and a beta of -0.12. The firm’s 50-day moving average is $1.54 and its 200-day moving average is $1.28.

Institutional Trading of Reviva Pharmaceuticals

An institutional investor recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.